Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Phentermine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 349Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vivus Commercializes QSIVA In Nordic Countries And Poland
    Vivus Commercializes QSIVA In Nordic Countries And Poland

    07 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/07/2958960/0/en/VIVUS-Announces-Commercialization-of-QSIVA-in-Sweden-Denmark-Finland-Iceland-Norway-and-Poland.html

    GLOBENEWSWIRE
    07 Oct 2024
    Share Share
    QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032
    QSYMIA (Phentermine-Topiramate) Drug Insights and Market Forecasts to 2032

    03 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/qsymia-phentermine-topiramate-drug-insights-and-market-forecasts-to-2032-301712347.html

    PR NEWSWIRE
    03 Jan 2023
    Share Share
    ICER reaffirms Qsymia as most cost-effective obesity treatment in final report
    ICER reaffirms Qsymia as most cost-effective obesity treatment in final report

    31 Aug 2022

    // Paul Schloesser ENDPTS

    https://endpts.com/icer-reaffirms-qsymia-as-most-cost-effective-obesity-treatment-in-final-report/

    Paul Schloesser ENDPTS
    31 Aug 2022
    Share Share
    FDA Approves Qsymia for Treating Teens With Obesity
    FDA Approves Qsymia for Treating Teens With Obesity

    29 Jun 2022

    // Miriam E. Tucker MEDSCAPE

    https://www.medscape.com/viewarticle/976307

    Miriam E. Tucker MEDSCAPE
    29 Jun 2022
    Share Share
    Fighting obesity by attacking both food intake and energy burn
    Fighting obesity by attacking both food intake and energy burn

    29 Jun 2019

    // Arlene Weintraub FIERCE BIOTECH

    https://www.fiercebiotech.com/research/fighting-obesity-by-attacking-both-food-intake-and-energy-burn?utm_source=internal&utm_medium=rss

    Arlene Weintraub FIERCE BIOTECH
    29 Jun 2019
    Share Share
    In another misstep for Vivus, FDA's promo police ding misleading Qsymia webpage
    In another misstep for Vivus, FDA's promo police ding misleading Qsymia webpage

    07 Jun 2019

    // Beth S. Bulik FIERCE PHARMA

    https://www.fiercepharma.com/marketing/prescription-drug-police-ding-vivus-for-misleading-qsymia-obesity-treatment-webpage

    Beth S. Bulik FIERCE PHARMA
    07 Jun 2019
    Share Share